Icaritin (Synonyms: Anhydroicaritin)

Name: Icaritin
Brand: MedChemExpress
SKU: HY-N0678
Rating: 5.0 (8 reviews)

Cat. No.: HY-N0678 Purity: 99.06%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis^[3.

For research use only. We do not sell to patients.

CAS No. : 118525-40-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Icaritin:

Icaritin (Standard) Get quote

8 Publications Citing Use of MCE Icaritin

Cell Proliferation/Viability Assay

Cell Imaging/Staining

RT-PCR

IHC

: Icaritin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May 21:143:156870. [Abstract]; Icaritin (0–50 μM; 48 h) significantly inhibited the growth of Huh7, CRL8024, SNU449, and HepG2 hepatocellular carcinoma cells in a dose-dependent manner.

: Icaritin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May 21:143:156870. [Abstract]; Icaritin (0–20 μM; 24 h) induced paraptotic cells in Huh7, CRL8024, SNU449, and HepG2 cell lines, with cytoplasmic vacuolation highlighted by red arrows.

: Icaritin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May 21:143:156870. [Abstract]; qRT-PCR quantification of mRNA expression levels of key ER stress-responsive genes (PERK, ATF4, HSPA5, and DDIT3) in SNU449 cells was performed after treatment with Icaritin (5-30 μM; 4-8 h).

: Icaritin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May 21:143:156870. [Abstract]; Icaritin (5-30 μM; 1-4 h) rapidly upregulated BHLHE40 expression in SNU449 and Huh7 cells, with levels increasing significantly in a dose- and time- dependent manner.

: Icaritin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May 21:143:156870. [Abstract]; Immunohistochemical images and Quantification for Ki67 and BHLHE40 staining in Huh7 cell (sh-NTC and sh-BHLHE40)-derived xenografts of NOD SCID mice with or without Icaritin (75 mg/kg; i.g.; once daily for 14 d) treatment.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

View All Isoforms

JAK1 JAK2 JAK3 Tyk2 JAK

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell viability by MTT assay Cytotoxicity against human A549 cells assessed as cell viability by MTT assay	[PMID: 26079090]
COS-7	IC₅₀	2.2 μM Compound: 3	Inhibition of human recombinant PDE5A1 expressed in COS7 cells Inhibition of human recombinant PDE5A1 expressed in COS7 cells	[PMID: 18778098]
Hep 3B2	IC₅₀	0.9 μM Compound: ICT; 1	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
HepG2	IC₅₀	> 10 μM Compound: ICT; 1	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
MCF7	IC₅₀	7 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay	[PMID: 26079090]
MDA-MB-435S	IC₅₀	24.9 μM Compound: 1	Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay	[PMID: 26079090]
NCI/ADR-RES	IC₅₀	52.09 μM Compound: 3	Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 19523827]
RPMI-8226	IC₅₀	20.78 μM Compound: Icaritin	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 34644502]
SMMC-7721	IC₅₀	> 10 μM Compound: ICT; 1	Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36745506]
Vero	IC₅₀	21.6 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay	[PMID: 26079090]

In Vitro

Icaritin (4-64 μM; 48 hours; K562, imatinib-resistant cells and primary CML cells) treatment inhibits proliferation of K562, imatinib-resistant cells and primary CML cells ^[1].
Icaritin (0-64 μM; 48 hours; K562 and primary cells) treatment induces K562 or primary cells apoptosis in an concentration dependent manner^[1].
Icaritin (32 μM; K562 cells) treatment increases cell population in the sub-G1 phase in K562 cells^[1].
Icaritin (0-64 μM; 48 hours; K562 cells) treatment inhibits MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression. Icaritin treatment also significantly inhibits Bcl-2 protein expression and up-regulated Bax protein expression in K562 with a dose-dependent manner accompanied by the cleavage activation of caspase-3 or caspase-9, and a down-regulated expression of Apaf-1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	K562, imatinib-resistant cells and primary CML cells
Concentration:	4 µM, 8 µM, 16 µM, 32 µM and 64 µM
Incubation Time:	48 hours
Result:	Inhibited cell proliferation.

Apoptosis Analysis^[1]

Cell Line:	K562 or primary cells
Concentration:	0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM
Incubation Time:	48 hours
Result:	Induced K562 or primary cells apoptosis.

Cell Cycle Analysis^[1]

Cell Line:	K562 cells
Concentration:	32 µM
Incubation Time:
Result:	Cell population in the sub-G1 phase was increased.

Western Blot Analysis^[1]

Cell Line:	K562 cells
Concentration:	0 µM, 4 µM, 8 µM, 16 µM, 32 µM and 64 µM
Incubation Time:	48 hours
Result:	Inhibited MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression.

In Vivo

Icaritin (4-8 mg/kg; intraperitoneal injection; daily; for 10 weeks; female NOD-SCID nude mice) treatment could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow in mouse leukemia model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NOD-SCID nude mice (6-8 weeks old) with K562 cells^[1]
Dosage:	4 mg/kg and 8 mg/kg
Administration:	Intraperitoneal injection; daily; for 10 weeks
Result:	Could prolong lifespan of NOD-SCID nude mice inoculated with K562 cells without suppression of bone marrow.

Clinical Trial

Molecular Weight

368.38

Formula

C₂₁H₂₀O₆

CAS No.

118525-40-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 15.62 mg/mL (42.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (27.15 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.06%

Select Batch:

Data Sheet (280 KB) SDS (396 KB)

COA (250 KB) HNMR (274 KB) RP-HPLC (250 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720. [Content Brief]

[2]. Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264. [Content Brief]

[3]. Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7146 mL	13.5729 mL	27.1459 mL	67.8647 mL
	5 mM	0.5429 mL	2.7146 mL	5.4292 mL	13.5729 mL
	10 mM	0.2715 mL	1.3573 mL	2.7146 mL	6.7865 mL
	15 mM	0.1810 mL	0.9049 mL	1.8097 mL	4.5243 mL
	20 mM	0.1357 mL	0.6786 mL	1.3573 mL	3.3932 mL
	25 mM	0.1086 mL	0.5429 mL	1.0858 mL	2.7146 mL
	30 mM	0.0905 mL	0.4524 mL	0.9049 mL	2.2622 mL
	40 mM	0.0679 mL	0.3393 mL	0.6786 mL	1.6966 mL

Icaritin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Icaritin118525-40-9AnhydroicaritinJAKAutophagyApoptosisJanus kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Icaritin (Synonyms: Anhydroicaritin)

Customer Review

Other Forms of Icaritin:

Icaritin Related Antibodies

8 Publications Citing Use of MCE Icaritin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Icaritin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Icaritin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report